logo-loader
viewSkinBioTherapeutics PLC

SkinBio sets out five channels for developing skin health technology

At the end of June, there was £3.1mln in the bank, compared to £3.2mln a year earlier

SkinBioTherapeutics PLC -
SkinBioTherapeutics is focused on application for skin health technology

SkinBioTherapeutics PLC (LON:SBTX) reported cash balances in line with expectations at the end of its financial year and said it has identified five “channels” for the development of its existing and new skin health technology.

In the year to 30 June, the AIM-listed company completed its first human cosmetic study, appointed Stuart Ashman as its chief executive and began the discussions that resulted in a first commercial deal earlier this month. 

READ: SkinBioTherapeutics teams up with Croda for first commercial deal

"This has been an exciting year for the company,” Ashman said in a statement. 

“The beginning of the year was about proving the sound scientific foundation of our SkinBiotix technology and the positive effects of it on the barrier function of the skin. The successful results drove commercialisation discussions forward which resulted in our recent agreement with the world leader in skincare actives for the cosmetic industry, Croda International Plc.”

Operating expenditure continued to increase during the course of the year, in line with management forecasts, with research and development spending of roughly £708,000, compared to £416,000 a year ago, which comprised of development work with the University of Manchester, ongoing work on manufacturing, scaling-up and formulation,  as well as the costs of the cosmetic human study.

Ongoing operating costs came in at roughly £652,000, compared to £526,000, covering employment, consultancy, PLC support costs and marketing.

At the end of June, there was £3.1mln in the bank, compared to £3.2mln a year earlier and with a £1.5mln share placing in February.

A strategic review has identified five channels for the company “to develop its focus”, including the core SkinBiotix technology, where the Croda agreement extends its applicability for use in cosmetic applications in active skincare, but SkinBio also sees opportunities to explore the technology's use in other areas, for example toothpaste and mouthwash.

MediBiotix, another channel, sees the technology platform targeted at medical device applications and with the current focus being the application of SkinBiotix technology on eczema, while the AxisBiotix channel focuses on the gut-skin axis and its role in various diseases, such as psoriasis.

Ashman says SkinBio's new financial year will see the company “continue to seek further commercial opportunities and build the development pipeline with new programmes in eczema and psoriasis” 

Quick facts: SkinBioTherapeutics PLC

Price: 13.5 GBX

AIM:SBTX
Market: AIM
Market Cap: £17.29 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

SkinBioTherapeutics inks commercial deal with FTSE 100 chemical firm Croda

SkinBioTherapeutics PLC's (LON:SBTX) CEO Stuart Ashman speaks to Proactive London's Andrew Scott after announcing they've inked a commercial agreement for its skincare product with FTSE 100 speciality chemical company Croda International Plc (LON:CRDA). Ashman says it's a significant first...

on 20/11/19

2 min read